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Neuroimaging biomarkers to predict 
treatment response in schizophrenia: 
the end of 30 years of solitude? 
Paola Dazzan, MD, PhD, FRCPsych
Studies that have used structural magnetic resonance imaging (MRI) suggest that individuals with psychoses have 
brain alterations, particularly in frontal and temporal cortices, and in the white matter tracts that connect them. 
Furthermore, these studies suggest that brain alterations may be particularly prominent, already at illness onset, in 
those individuals more likely to have poorer outcomes (eg, higher number of hospital admissions, and poorer symp-
tom remission, level of functioning, and response to the first treatment with antipsychotic drugs). The fact that, 
even when present, these brain alterations are subtle and distributed in nature, has limited, until now, the utility 
of MRI in the clinical management of these disorders. More recently, MRI approaches, such as machine learning, 
have suggested that these neuroanatomical biomarkers can be used for direct clinical benefits. For example, using 
support vector machine, MRI data obtained at illness onset have been used to predict, with significant accuracy, 
whether a specific individual is likely to experience a remission of symptoms later on in the course of the illness. 
Taken together, this evidence suggests that validated, strong neuroanatomical markers could be used not only to 
inform tailored intervention strategies in a single individual, but also to allow patient stratification in clinical trials 
for new treatments.           
© 2014, AICH – Servier Research Group  Dialogues Clin Neurosci. 2014;16:491-503.
Introduction
 Why have we not been able to use neuroimag-
ing in the clinical management of psychoses? After 30 
years of using this approach, we have established that 
structural brain alterations are present in individuals 
with psychoses. While this information has advanced 
academic knowledge on the pathophysiology of these 
disorders, it has had limited utility in clinical practice. 
The main reason can be found in the nature of brain al-
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terations in psychoses: they are subtle and spatially dis-
tributed. Still, the time may now have come when quick 
and noninvasive structural neuroimaging abandons the 
academic solitude in which it has been operating, and 
brings its novel methods and findings into the clinical 
arena. This paper aims to appraise this evidence, and 
discuss it in the context of potential future applications 
of magnetic resonance imaging (MRI) in the clinical 
management of psychoses. 
 The first part of this review will present evidence 
on the presence of neuroanatomical alterations in psy-
choses. It will then discuss studies that have examined 
the relationship between brain alterations and vari-
ous medium- to long-term clinical and functional out-
comes. In the third section, it will discuss more recent 
evidence on the relationship between brain alterations 
and early outcomes, with a particular focus on the re-
lationship between symptomatic responses and initial 
treatment with antipsychotic drugs. The paper will 
then present a discussion of more novel approaches 
for the analysis of MRI data, such as support vector 
machine. Findings from these approaches have started 
to suggest that MRI has the potential to provide clini-
cally meaningful information. Finally, it will discuss the 
implications of having strong and valid neuroimaging 
markers of psychosis outcomes in developing targeted, 
as well as novel, treatment interventions for these dis-
orders. 
Structural brain alterations 
in psychosis
Moving from the first evidence that individuals with 
established schizophrenia have subtle structural brain 
alterations, most notably an enlargement of the lat-
eral ventricles, we have been studying individuals ear-
lier and earlier along the disease course. More than 10 
years ago, the seminal work by Pantelis and colleagues1 
showed that individuals at high risk of developing psy-
chosis, but not ill yet, already show smaller volumes of 
the same brain areas that have been reported as smaller 
in individuals with an established psychosis, namely 
frontal and temporal cortices.1 Even more novel, how-
ever, was their report that this is particularly the case 
for individuals who then actually develop the illness, 
and that some of these alterations could be specific to 
the type of psychosis that these subjects developed.1,2 
For example, they found that subjects who develop an 
affective type of psychosis showed reductions in the 
subgenual anterior cingulate cortex, an area involved 
in the generation of affective symptoms. Complemen-
tary to these gray-matter changes, ultra-high-risk indi-
viduals also have white matter alterations similar to, 
albeit less extensive than, first-episode patients. These 
include poorer integrity of the major associative fibers 
that connect fronto-parieto-temporal (superior longitu-
dinal fasciculus) and fronto-parieto-occipital (inferior 
fronto-occipital fasciculus) regions, commissural fibers 
(corpus callosum), and cortico-subcortical pathways 
(corona radiata, corticospinal tract, and corticopontine 
tract).3 These findings, integrated with evidence from 
many reviews and meta-analyses, suggest that brain al-
terations become more extensive at the time of a first 
full psychotic episode, and then possibly even more 
marked over the years, when the illness becomes es-
tablished.4-6 Still, even in later stages, alterations remain 
subtle and distributed. These are indeed two main fac-
tors that have limited our ability to use this information 
about brain alterations in the clinical management of 
the individual patient.  
 Therefore, many studies have tried to establish 
whether these distributed brain changes are more 
likely to occur in individuals with a more severe illness 
course or a worse clinical and functional outcome. The 
definitions for course and outcome have varied across 
studies. For example, a poorer clinical outcome has 
been variously defined as response to early treatment, 
number of subsequent episodes, severity of symp-
toms, hospitalizations, or duration of remissions; while 
functional outcome has been defined as the ability to 
live independently, maintain employment, or be in a 
relationship. Nevertheless, many studies have tried to 
establish if structural brain alterations are related to 
illness characteristics by comparing brain structure in 
patients and healthy controls and then evaluating the 
relationship with outcomes at a single time point; or 
conducting repeated evaluations of brain structure, 
and then investigating the relationship between lon-
gitudinal brain changes and outcomes. Most of these 
studies have evaluated the relationship with medium 
to long-term outcomes, and only more recently has the 
attention shifted to the evaluation of the relationship 
between brain alterations and early outcomes such as 
response to the first treatment. The next two sections 
will cover this evidence in the same chronological or-
der. 
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Brain structure and its relationship 
with medium- to long-term clinical 
and functional outcomes
Studies that have evaluated brain structure at the time of 
illness onset and again following treatment, have often 
reported smaller volumes of gray matter in association 
with indicators of subsequent poorer clinical outcomes 
(eg, higher number of admissions or worse symptom se-
verity), and with worse social or occupational outcomes. 
For example, smaller volumes of prefrontal areas have 
been found to predict poorer functioning (defined as a 
combination of social, occupational, and psychological 
functioning) 1 year later in a small sample of first-episode 
psychosis patients.7 Similarly, in a sample of patients with 
schizophrenia, drawn from an unselected general popu-
lation sample, Jääskeläinen and colleagues8 found that 
individuals showing higher density (an indirect measure 
of volume) of frontal and limbic areas had an overall 
better clinical (defined as a lower number of hospitaliza-
tions) and functional (defined as not being on a disability 
pension) outcome in the subsequent 16 years. Wassink 
and colleagues9 reported an association between smaller 
volumes of another brain area, the cerebellum, and lon-
ger negative and psychotic symptom duration, as well 
as psychosocial impairment (eg, quality of relationships, 
sexual activity, enjoyment of recreation, and work per-
formance) in individuals with schizophrenia spectrum 
disorders after a 7-year follow-up. Still, others have not 
found an association between brain volumes at onset and 
subsequent outcomes. For example, the prospective study 
by van Haren and colleagues10 found no relationship be-
tween brain volume measurements and symptom sever-
ity, level of functioning (defined as the ability to maintain 
a variety of social roles), need for care, and illness course 
after 2 years. White matter has also been evaluated as a 
marker of poor outcome. Mitelman and colleagues11 ex-
amined white matter integrity using diffusion tensor im-
aging (DTI), in a group of 104 patients with an average 
4-year schizophrenia duration. They classified them as 
having a poor or good outcome, based on both symptom 
severity and level of functioning at this time point. They 
found that although both patient groups showed reduced 
overall white matter integrity of the prefrontal and tem-
poral areas (as a measure of fractional anisotropy [FA]), 
these alterations were more extensive in patients with a 
poor outcome than in those with a good outcome.
 Longitudinal studies that have evaluated brain 
structure at multiple time points after illness onset can 
help clarify if brain alterations, evident at illness onset, 
progress differently in individuals who then developed 
a poorer outcome. For example, a larger decrease in the 
volume of the lingual gyrus, insula, and cerebellum has 
been reported in patients with a worse functional out-
come (a combination of social, occupational, and psy-
chological functioning) 4 years after the first psychotic 
episode.12 With a similar duration of follow-up, van Har-
en and colleagues also reported a greater gray matter 
volume reduction, and a greater thinning of temporal 
and frontal cortices in individuals who had poorer out-
comes (including a higher number of hospitalizations 
and a lower level of social and personal functioning) 
5 years after illness onset.13,14 Similarly, in a sample of 
children and adolescents with early onset first-episode 
schizophrenia, Arango and colleagues15 showed that 
more weeks of hospitalization and higher severity of 
negative symptoms were correlated with greater left 
frontal gray matter volume loss and greater cerebral 
spinal fluid increase, respectively. Dynamic changes in 
relation to outcomes were also observed by our group 
in a 6-year follow-up study of hippocampal volume in 
first-episode psychosis patients.16 In this sample, we 
specifically found that individuals who had an increase 
in hippocampal volume over the first 6 years of illness 
were the ones who showed a less severe illness course 
and lower symptom severity, as well as a better func-
tional outcome at follow-up, thus suggesting an impor-
tant role for brain neuroplasticity. 
 Taken together, these findings suggest that brain al-
terations are present at illness onset and may be associ-
ated with worse medium- to long-term illness outcomes 
and ability to function. Furthermore, brain alterations 
may particularly progress in individuals with more se-
vere outcomes. Still, two important considerations need 
to be made in the interpretation of these findings. First, 
it is not possible to establish what the casual link is be-
tween brain structure and illness course. While brain al-
terations could be the substrate of a more severe illness, 
the more severe illness itself could affect brain plasticity 
by increasing exposure to substance abuse, worse living 
conditions, or a less stimulating environment. Second, 
these patients are all treated after illness onset. It is, 
therefore, possible that patients with a more severe ill-
ness are exposed to longer periods of treatment or high-
er doses of antipsychotics, which may themselves affect 
brain volumes.17 From a clinical perspective, it may be 
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more informative to study the relationship between 
brain alterations at illness onset and outcome measures 
that occur earlier in the course of illness, which is the 
topic of the next section.
Brain structure and its relationship 
with early outcomes
If brain alterations could be used to predict, as early as 
possible, which patients are destined to have a poorer 
response to the first few weeks or months of treatment 
with antipsychotic medications (the main stake for the 
treatment of psychosis), we could implement inter-
ventional strategies targeted at this specific subgroup. 
Currently, we treat the first psychotic episode on a trial- 
and-error basis, and we simply have no way of saying 
who will respond to the first antipsychotic drug and who 
might benefit from longer or different interventions. In 
fact, we know that only ≈55% of patients respond to 
antipsychotics in the first 12 months of treatment.18 Yet, 
this early response is thought to be one of the strongest 
predictors of subsequent functional and clinical out-
comes in psychosis.19,20
 A pooled analysis, published in 1992, examined the 
relationship between response to antipsychotics and 
brain measures, such as ventricular-brain ratio, sulcal 
prominence, third ventricles, and other brain mea-
sures.21 The authors found that the composite effect 
sizes were very small and did not reach statistical sig-
nificance. However, recent studies have lent renewed 
support to the notion that alterations in both gray 
and white matter may be associated with a poorer re-
sponse to antipsychotics, possibly because they used 
more homogeneous populations, or in some cases, bet-
ter imaging acquisition approaches and more sophisti-
cated methods of analysis. For example, Zipursky and 
colleagues22 examined global tissue volumes in first-
episode psychosis patients, and found that subjects 
with a poorer response (defined as having a lower re-
duction in symptom severity from baseline) to the an-
tipsychotic haloperidol in the first month of treatment 
had smaller cortical gray matter volume than those 
who showed symptomatic improvement. Relatively 
consistent data have been reported on the relationship 
between response to clozapine and brain structure. 
Cortical measures, such as sulcal enlargement, partic-
ularly in the prefrontal cortex, have been frequently 
related to poor response to clozapine in patients with 
chronic schizophrenia.23-25 In a double-blind, 10-week 
trial of clozapine and haloperidol, Arango and col-
leagues26 found that a larger prefrontal gray matter 
volume was associated with better treatment response 
in clozapine-treated patients, but with a poor response 
in haloperidol-treated patients. They also found no re-
lationship between response to these drugs and hippo-
campal and caudate nucleus volumes. The authors sug-
gested that the presence of larger brain volumes might 
characterize patients who are more likely to benefit 
from clozapine. This finding is also consistent with evi-
dence from a study in patients with treatment-resistant 
schizophrenia who were treated for with clozapine 6 
months.27 Patients with a larger baseline volume of 
the dorsolateral-prefrontal cortex were more likely to 
show improvement in their negative symptoms. Inter-
estingly, amelioration of positive symptoms was related 
to a larger temporal cortex volume, and amelioration 
of disorganization symptoms was inversely related to 
hippocampal volume. Another temporal area has been 
reported as being related to early outcome—the para-
hippocampal gyrus. Using voxel-based morphometry, 
Bodnar and colleagues28 found that the parahippo-
campal gyrus was significantly smaller in first-episode 
psychosis patients who, after 6 months of antipsychotic 
treatment, had not remitted, compared with those who 
had achieved remission. Furthermore, by building a 
classification model using parahippocampal gray mat-
ter concentration, they were able to correctly classify 
remission status in 79% of the cases. In another study 
of patients with established schizophrenia treated with 
olanzapine or risperidone, 3-week response to these 
antipsychotics was associated with smaller volumes of 
other areas, such as the insula and rectal gyrus, and 
larger volumes of the basal ganglia.29
 White matter has also been associated with treat-
ment response, but the evidence is considerably more 
scant. Response to antipsychotics was evaluated by 
Garver and colleagues in a small sample of patients 
with schizophrenia after 28 days of treatment.30 Here, 
somewhat counterintuitively, the 8 patients who re-
sponded to antipsychotics showed worse white matter 
microstructural integrity than the 5 patients who did 
not respond to medication. Of note, individuals, in this 
study, had an established illness, and therefore, had 
taken other antipsychotics prior to this treatment. In 
contrast, studies in antipsychotic naive or minimally 
treated patients have the advantage that any structur-
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al brain alterations would be less likely to reflect the 
effect of antipsychotics on brain structure,17 and more 
likely to be a marker of illness. Luck and colleagues31 
analyzed a sample of first-episode psychosis patients 
using DTI, and then reassessed them at 6 months, 
which is when they classified them as having either 
a poor or good treatment outcome. They specifically 
examined three white matter tracts connecting fron-
tal and temporal regions: the cingulum, the superior 
longitudinal fasciculus, and the uncinate fasciculus. Pa-
tients with a poor outcome showed greater alterations 
in white matter integrity in the superior longitudinal 
fasciculus and uncinate than patients with a good out-
come, suggesting that abnormal fronto-temporal con-
nectivity may represent an early marker of short-term 
clinical outcomes. 
 Our group has also recently focused on the evalua-
tion of the relationship between neuroanatomical mark-
ers in white and gray matter at the time of presentation, 
and response to treatment at 12 weeks.32,33 This is a time 
when all patients would have received at least one full 
therapeutic course of antipsychotic medication. We 
examined white matter integrity, using DTI and tract-
based spatial statistics, to assess FA in a large sample of 
patients at their first episode of any psychosis.33 We op-
erationalized response to treatment as having achieved 
symptomatic remission according to the criteria of the 
Schizophrenia Working Group.34 We found that already 
at illness onset, patients who subsequently did not re-
spond (n=40) had lower FA than healthy controls in the 
uncinate, cingulum, and corpus callosum. Furthermore, 
they also had lower FA in these regions than patients 
who responded to treatment (n=40; Figure 1, Tables I 
and II). 
 One of the most striking findings of this work was 
that the responders were indistinguishable from the 
healthy control subjects, suggesting that the original 
clinical sample was biologically rather heterogeneous. 
We rescanned these subjects at the 12-week clinical 
evaluation, and found that the same regional differ-
ences seen at baseline between the two patient groups 
were also present at 12 weeks, although the differenc-
es appeared less widespread. Furthermore, although 
there was some increase in FA over time, this was in 
the same direction in the two patient groups, with no 
significant time vs group interaction. We interpreted 
these findings to indicate that white matter integrity 
and brain connectivity are important moderators of 
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Figure 1.  White matter maps of differences between nonresponders and responders. The figure shows areas of significantly decreased fractional 
anisotropy in nonresponders when compared with responders, at baseline (A) (P<0.05; Family-Wise Error [FEW]-corrected) and at 
12-week follow-up (B) (P<0.05; FWE-corrected). Fractional anisotropy white matter skeleton is represented by green voxels displayed 
on a background image that corresponds to the mean fractional anisotropy image in standard Montreal Neurological Institute (MNI) 
MNI152 brain space (radiological view), with the coordinate number on top. Red-yellow voxels represent regions in which the fractional 
anisotropy was significantly lower in the nonresponder group relative to the responder group.
  From reference 33: Reis Marques TR, Taylor H, Chaddock CA, et al. White matter integrity as predictor of response to treatment in first episode psychosis. 
Brain. 2014;137:172-182. © 2013, Oxford University Press.
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response to antipsychotics. It is intriguing to specu-
late whether these alterations are established early on, 
as a neurodevelopmental deviation. The presence of 
a neurodevelopmental alteration would find further 
support in our gray matter findings from this sample.32 
In these individuals, we performed the first 3D evalu-
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JHU white matter atlas region
Significant 
cluster size 
(nº voxels)
Region 
significant 
(%)a
t-statistic
MNI coordinates of peak 
voxel (mm)
X Y Z
Uncinate
       Left 70 91% 3.38 -33 -6 -14
       Right 59 86% 2.24 35 -4 -14
Fornix
       Left stria terminalis 270 76% 2.98 -34 -11 -15
       Right stria terminalis 11 4% 2.64 34 -11 -15
Corticospinal
       Left 203 75% 1.92 9 -29 -23
       Right 135 51% 3.02 10 -27 -27
Cerebral peduncle
       Left 436 72% 2.35 -9 -29 -20
       Right 360 59% 3.40 10 -28 -19
External capsule
       Right 781 67% 2.48 36 -7 -13
       Left 790 61% 4.36 -35 -8 -13
Internal capsule
       Left posterior limb 575 66% 2.64 -20 -14 0
       Right anterior limb 480 58% 3.24 10 1 1
       Left retrolenticular limb 372 47% 2.44 -24 -19 0
       Left anterior limb 361 43% 3.00 -13 -1 4
Corpus callosum
       Body 1985 63% 2.70 -13 17 24
       Genu 1039 60% 3.55 -15 32 14
       Splenium 1145 46% 2.13 1 -31 21
Corona radiata
       Right anterior 1005 63% 3.26 27 28 10
       Left anterior 942 56% 3.75 -15 33 15
       Left posterior 364 48% 1.27 -21 -44 35
       Left superior 578 42% 2.36 -22 -25 36
       Right superior 591 42% 3.21 21 -16 36
       Right posterior 153 20% 2.67 30 -60 19
Table I.  White matter regions of fractional anisotropy reduction between nonresponders and responders at baseline. JHU, Johns Hopkins Univer-
sity; MNI, Montreal Neurological Institute. aObtained by dividing the number of significant voxels within each regional mask by the total 
number of voxels in that mask.
  From reference 33: Reis Marques TR, Taylor H, Chaddock CA, et al. White matter integrity as predictor of response to treatment in first episode psychosis. 
Brain. 2014;137:172-182. © 2013, Oxford University Press.
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Table II.  White matter regions of fractional anisotropy reduction between nonresponders and responders at 12-weeks follow-up. JHU, Johns 
Hopkins University; MNI, Montreal Neurological Institute. aObtained by dividing the number of significant voxels within each regional 
mask by the total number of voxels in that mask.
  From reference 33: Reis Marques TR, Taylor H, Chaddock CA, et al. White matter integrity as predictor of response to treatment in first episode psychosis. 
Brain. 2014;137:172-182. © 2013, Oxford University Press.
Table I.  Continued
Cerebellar peduncle
       Left superior 99 48% 2.16 -5 -30 -21
       Right superior 90 36% 2.46 7 -31 -16
       Left inferior 66 33% 1.97 -13 -45 -32
       Middle 753 33% 3.19 -23 -46 -36
Pontine cross tract 98 25% 2.35 -2 -30 -30
Medial lemniscus
       Left 61 24%     2.13 -4 -38 -37
       Right 30 12% 2.10 6 -34 -25
Superior frontal occipital
       Right 18 23% 1.52 23 2 19
       Left 9 10% 1.45 -21 5 19
JHU white matter atlas region
Significant  
cluster size      
(nº voxels)
Region  
significant 
(%)a
t-statistic
MNI coordinates of peak 
voxel (mm)
X Y Z
Uncinate 
        Left 58 81% 2.48 -34 -6 -14
        Right 65 96% 1.88 36 -3 -16
External capsule 
        Left 831 64% 4.61 -33 -6 -13
        Right 341 29% 2.55 36 -7 -13
Corona radiata
       Left anterior 1014 59% 2.70 -15 36 -1
       Right anterior 978 59% 3.49 23 19 18
       Left superior 760 54% 3.56 -22 -25 35
       Right superior 292 21% 3.47 23 -19 38
       Left posterior 406 53% 2.19 -26 -30 27
       Right posterior 21 3% 1.76 19 -26 35
Fornix
       Left stria terminalis 202 58% 2.55 -28 -26 -8
       Right stria terminalis 10 3% 2.63 34 -11 -15
Internal capsule 
       Left anterior limb 446 53% 2.51 -17 6 9
       Right anterior limb 327 39% 3.13 21 4 15
       Left retrolenticular limb 286 36% 2.01 -26 -24 8
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ation of cortical gyrification, a marker potentially in-
dicative of early neurodevelopmental disturbances,35,36 
in relation to subsequent treatment response. Gyrifi-
cation defects have been associated with exposure to 
obstetric complications37,38 and with psychotic symp-
toms resistant to treatment.39 Interestingly, the earlier 
neuroimaging studies in treatment-resistant patients 
that were mentioned in the previous section, found 
that sulcal enlargement (which could lead to hypogy-
ria) was associated with a poorer response to clozap-
ine.23-25 In our samples, we found that, already at illness 
onset, patients who subsequently did not respond to 
treatment had significant cortical folding defects (hy-
pogyria) of several frontotemporal regions and the 
insula when compared with the responders. They also 
had widespread deficits in gyrification extending to the 
precuneus, angular gyrus, and lingual gyrus when com-
pared with healthy controls (Figure 2, Table III). 
 In contrast, and similarly to what we saw for white 
matter, patients who subsequently responded were vir-
tually indistinguishable from the healthy controls. These 
findings are very consistent with the evidence described 
earlier that only the nonresponders have reduced integ-
rity in the white matter tracts that connect these corti-
cal regions.33 It is also interesting that the alterations 
in gyrification and white matter were evident in nonre-
sponders with both affective (bipolar disorder or major 
depression with psychotic symptoms) and nonaffective 
(schizophrenia, schizophreniform disorder, schizoaf-
fective disorder and psychosis not otherwise specified) 
psychosis, suggesting that as a group, nonresponders are 
likely to have a more homogeneous pathophysiologi-
cal process underlying psychoses than the responders. 
Taken together, these findings suggest that individuals 
who are less likely to respond to treatment represent 
either a more severely affected group, or a group that 
has experienced a pathophysiological insult at an early 
neurodevelopmental stage than those who respond to 
treatment, possibly with a differential exposure to fac-
tors that determine axonal integrity (genetic or molec-
ular), which, in turn, influences brain connectivity and 
gyrification. 
 Although crucial to our understanding of psychosis, 
these group findings need to be extended if they are to 
inform clinical outcomes at the level of a single indi-
vidual.
Table II.  Continued
       Left posterior limb 160 18% 1.42 -22 -9 11
       Right posterior limb 88 10% 2.25 20 -4 10
Corpus callosum
       Genu 806 46% 2.91 -13 33 -3
       Body 725 23% 3.01 15 17 25
       Splenium 377 15% 2.10 -23 -54 17
Superior frontal occipital 
       Left 34 35% 2.25 -21 14 19
       Right 26 32% 1.27 23 2 19
Superior longitudinal fasciculus
        Left 331 24% 2.36 -35 -25 35
        Right 367 24% 1.89 38 -39 28
Thalamic radiation 
       Left posterior 207 19% 1.73 -28 -53 18
Inferior longitudinal fasciculus
        Left sagittal stratum 38 8% 2.54 -35 -11 -14
        Right sagittal stratum 7 1% 2.19 36 -11 -14
Cingulum
        Right 25 7% 2.30 10 17 26
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Moving toward using brain structure 
at illness onset in the individual 
prediction of outcome
Structural imaging has strong potential for clinical ap-
plicability as it is: (i) noninvasive; (ii) quick to acquire; 
(iii) widely available; and finally, (iv) cheap compared 
with other imaging methods such as positron emission 
tomography. Therefore, what progress have we made 
toward its clinical applicability? 
 Over the last few years, the application of novel ap-
proaches to the analysis of structural imaging data has 
made us feel closer to their potential use in clinical man-
agement. To this end, machine-learning methods, such 
as support vector machine, have shown promise in dif-
ferentiating patients or ultra-high-risk individuals from 
healthy controls, based on structural MRI data.40-42 Ob-
viously, an even more interesting translational question 
would be: can we use structural MRI data at illness on-
set to predict which individuals will develop worse out-
comes or poorer responses to treatment? About 2 years 
ago, our group published the first paper showing that 
structural brain scans at the first episode could be used 
to predict, with significant accuracy, outcomes at 6 years. 
In this study, we found that the MRI scan obtained when 
patients first presented to services could be used to pre-
dict which patients developed a continuous nonremitting 
illness course; distinguishing them from both healthy 
controls (sensitivity, 71; specificity, 61) and from patients 
who had an episodic, more benign illness (sensitivity, 71; 
specificity, 68). Consistent with our recent data, discussed 
in the previous section, we were not able to distinguish 
the patients who went on to have an episodic course 
from the healthy controls.43 Other papers have since con-
firmed, in different clinical populations, the potential of 
machine-learning approaches to discriminate individual 
patients in predicting the onset and subsequent sever-
ity of psychosis in ultra-high-risk individuals.44,45 While 
promising, these approaches need replication in larger 
samples of patients at the same illness stages and treat-
ed with the same pharmacological interventions, and 
also need validation for scans obtained using different 
scanners. These are just some of the aims of an ongoing, 
large, multicenter study funded by the FP7 Programme 
of the European Commission, OPTiMiSE (OPtimiza-
tion of Treatment and Management of Schizophrenia in 
Europe, www.optimisetrial.eu). Across various centers in 
Europe, we are acquiring MRI scans from a very large 
sample of patients with first-episode schizophrenia, who 
are then all treated with the same antipsychotic, amisul-
pride, for 4 weeks, when their symptomatic response is 
evaluated. This study will use both univariate and mul-
tivariate image analysis approaches, ie, support vector 
machine, to establish whether it is possible to predict the 
4-week response based on the MRI scan obtained at the 
first episode, alone or in combination with, other biologi-
cal markers, including magnetic resonance spectroscopy. 
Conclusion
We know that the outcome and response to available 
treatments for schizophrenia, and for psychosis in 
general, is heterogeneous. Still, we do not have strong 
biological markers that could help us disentangle this 
heterogeneity and be useful in clinical practice. There 
are, however, structural brain alterations that, if refined, 
have potential for use early in the stratification of pa-
Figure 2.  Voxel clusters showing differences in gyrification among re-
sponders, nonresponders, and healthy controls. Clusters of 
spatially contiguous suprathreshold voxels indicating higher 
gyrification for each between-group comparison are dis-
played in red, yellow, and purple. There were no clusters of 
reduced gyrification in these between-group comparisons. 
All clusters are displayed on a reconstructed average white 
matter surface (fsaverage in the FreeSurfer software) and 
survived multiple testing using Monte Carlo simulation with 
a cluster inclusion criterion of P=0.05. The left hemisphere is 
on the left side of the image, and the right hemisphere is on 
the right side. The exact values of clusterwise probability for 
the clusters are presented in Table III.
  From reference 32: Palaniyappan L, Marques TR, Taylor H, et al. Cor-
tical folding defects as markers of poor treatment response in first-
episode psychosis. JAMA Psychiatry. 2013;70:1031-1040. Copyright 
© 2013, American Medical Association.
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Cortical region Talairach coordinates 
of the peak
Cluster size 
(mm2)
Clusterwise probability
Healthy controls > all patients
Left posterior cingulate/precuneus -8,-40,41 8304 0.0001
Left precentral -41,-12,48 3589 0.0001
Left middle/inferior frontal -35,36,12 1167 0.0440
Right middle frontal cortex 33,23,43 1304 0.0003
Right inferior parietal 45,-58,36 755 0.0364
Responders > nonresponders
Left insula/central sulcus -57,-8,10 3697 0.0001
Right insula/lateral temporal 37,-13,2 6703 0.0001
Left superior frontal/mid-cingulate -9,32,27 5080 0.0001
Left middle frontal gyrus -35,51,-1 2581 0.0001
Healthy controls > nonresponders  
Left posterior cingulate/precuneus -9,-49,26 7219 0.0001
Left precentral -37,7,37 3775 0.0001
Right superior/middle frontal 20,33,34 3415 0.0001
Right superior temporal 53,-30,3 1811 0.0001
Right cuneus/lingual gyrus 10,-58,2 4382 0.0001
Right insula/lateral temporal 37,-13,2 4502 0.0001
Left middle frontal -38,43,5 2330 0.0001
Right angular gyrus 45,-59,36 1415 0.0020
Left inferior temporal -53,-28,-24 792 0.0244
Left orbitofrontal -33,20,-17 1077 0.0030
Healthy controls > responders
Left lingual -4,-82,1 862 0.0151
Non-affective psychosis < affective psychosis
Right insula/superior temporal 37,-12,2 5778 0.0001
Right inferior temporal 51,-27,-22 7245 0.0001
Left insula/inferior frontal -42,19,7 5870 0.0001
Left middle frontal -22,44,20 1037 0.0049
Right subgenual anterior cingulate 7,15,-17 1245 0.0007
Right posterior cingulate/precuneus 41,-81,6 1809 0.0001
Left lateral occipitotemporal -49,-62,-2 4116 0.0001
Left posterior cingulate -4,-15,31 1310 0.0004
Table III.  Group differences in gyrification among responders, nonresponders and healthy controls. The threshold for inclusion into a cluster is P<0.05.
  From reference 33: Reis Marques TR, Taylor H, Chaddock CA, et al. White matter integrity as predictor of response to treatment in first episode psychosis. 
Brain. 2014;137:172-182. © 2013, Oxford University Press.
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tients with psychosis. For this to be achieved, a number 
of steps still have to take place. For example, validation 
with very large datasets could help establish a reference 
group (a “databank”), which clinical imaging centers 
could access for an automated classification of their pa-
tients’ MRIs in order to obtain an estimate of the likeli-
hood of a specific outcome. For this to be achieved, it 
would be essential to have standardized definitions of 
outcomes within the clinical academic community that 
are relevant to clinicians, patients, and their careers.
 Such a system could then be used to assign a patient 
to targeted assertive case management at first presenta-
tion to services, in the optimization of pharmacologi-
cal treatment, or in cognitive and family interventions. 
These have all been shown to improve treatment ad-
herence and reduce relapse rates,46,47 eventually im-
proving outcome. At the same time, they could help 
identify those patients most likely to have a good re-
mitting illness after their first episode, who could then 
avoid long-term exposure to antipsychotic medication. 
Furthermore, the identification of gray matter and con-
nectivity markers that characterize poor response poses 
the question of whether these markers could be used 
in patient stratification in clinical trials of new treat-
ment strategies, or even to inform drug development of 
agents that can enhance and restore brain connectivity, 
which may elicit a better response in those who cur-
rently do not respond to available antipsychotics. o
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Las neuroimágenes como biomarcadores para 
predecir la respuesta terapéutica en la 
esquizofrenia: el final de treinta años de 
aislamiento
Los estudios que han empleado imágenes de resonancia 
magnética estructural (IRM) sugieren que los sujetos con 
psicosis tienen alteraciones cerebrales, especialmente 
en las cortezas frontal y temporal, y en los tractos de 
sustancia blanca que las conecta. Además, dichos estu-
dios sugieren que las alteraciones cerebrales pueden 
ser muy importantes, ya al inicio de la enfermedad, en 
aquellos individuos con más probabilidades de tener 
peor pronóstico (por ejemplo, mayor número de hospi-
talizaciones, peor remisión sintomática, menor nivel de 
funcionamiento y peor respuesta al primer tratamiento 
con antipsicóticos). De hecho,  cuando estas alteracio-
nes cerebrales están presentes, ellas son leves y se dis-
tribuyen en cualquier parte, por lo que hasta la fecha 
la utilidad de la IRM es limitada en el manejo clínico de 
estos trastornos. Recientemente los planteamientos de 
la IRM, a partir de las técnicas aprendizaje máquina, han 
sugerido que estos biomarcadores neuroanatómicos 
pueden  ser empleados con beneficios clínicos directos. 
Por ejemplo, empleando las técnicas de máquinas sopor-
te de vectores para regresión, los datos obtenidos con 
IRM al comienzo de la enfermedad han sido útiles para 
predecir, con precisión significativa, si un sujeto deter-
minado puede experimentar más adelante una remisión 
sintomática durante el curso de la enfermedad. En su 
conjunto esta evidencia sugiere que los marcadores bien 
establecidos y validados podrían emplearse no solo para 
informar sobre estrategias de intervención a la medida 
en un paciente individual, sino también para asignar la 
estratificación de pacientes en ensayos clínicos de nue-
vos tratamientos.   
Biomarqueurs de neuro-imagerie pour prédire la 
réponse au traitement dans la schizophrénie : 
la fin de 30 ans de solitude ?
Selon les études de la structure cérébrale avec l’imagerie 
par résonance magnétique (IRM), les sujets psychotiques 
présentent des modifications, particulièrement dans 
les cortex frontal et pariétal, et dans les faisceaux de 
substance blanche qui les relient. Au début de la mala-
die, ces modifications seraient prédominantes chez les 
sujets plus susceptibles d’évoluer défavorablement (par 
exemple, un plus grand nombre d’hospitalisations, une 
moins bonne rémission des symptômes, un niveau de 
fonctionnement et une réponse moins bons au premier 
traitement par antipsychotiques). Le fait que ces modi-
fications cérébrales, même lorsqu’elles sont présentes, 
sont discrètes et de nature diffuse a limité jusqu’à pré-
sent l’utilité de l’IRM dans la prise en charge clinique 
de ces maladies. Plus récemment, des techniques d’IRM 
comme celles fondées sur un auto-apprentissage par la 
machine, ont suggéré que ces biomarqueurs neuro-ana-
tomiques peuvent être utilisés en vue de bénéfices cli-
niques. Par exemple, à l’aide d’une machine à vecteurs 
de support, les données IRM obtenues au début de la 
maladie ont permis de prédire, avec une précision signi-
ficative, chez un patient donné, la probabilité d’une 
rémission plus ou moins tardive des symptômes au cours 
de l’évolution de la maladie. L’ensemble de ces données 
suggèrent que des marqueurs neuro-anatomiques vali-
dés seraient utiles non seulement pour individualiser le 
traitement chez un patient donné, mais aussi pour stra-
tifier les patients dans des groupes lors des études cli-
niques de nouveaux traitements.
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